0000000000693478

AUTHOR

Francesco Raspagliesi

showing 7 related works from this author

SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

2021

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 da…

Malepulmonary embolismInternationalitySettore MED/18 - CHIRURGIA GENERALEDeep veinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]infectious diseasesCardiovascularSARS‐CoV‐2surgeryCOVID-19 ; SARS-CoV-2 ; deep vein thrombosis ; pulmonary embolism ; venous thromboembolismCohort StudiesPostoperative ComplicationsAnesthesiologyMedicine and Health SciencesProspective Studies610 Medicine & healthProspective cohort studyLung11 Medical and Health SciencesConfoundingHematologyMiddle AgedThrombosis17 Psychology and Cognitive SciencesCOVID-19; deep vein thrombosis; pulmonary embolism; SARS-CoV-2; venous thromboembolismPulmonary embolismCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolism.medicine.anatomical_structureCohortCOVID-19/complicationsPostoperative Complications/etiologyOriginal ArticleFemalePatient SafetyLife Sciences & BiomedicineCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolismHumanAdultmedicine.medical_specialtyAdolescentClinical Sciencesvenous thromboembolism610 Medicine & healthGlobalSurg CollaborativeVenous Thromboembolism/etiologydeep vein thrombosisNOCOVIDSurg CollaborativeYoung AdultMedicine General & InternalAge DistributionClinical ResearchCOVID‐19General & Internal MedicinemedicineHumansSex DistributionAgedScience & Technologybusiness.industrySARS-CoV-2PreventionNeurosciencesdeep vein thrombosiCOVID-19PneumoniaOdds ratioOriginal Articlesmedicine.diseaseSurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Prospective StudieGood Health and Well BeingAnesthesiology and Pain MedicineHuman medicinePostoperative ComplicationCohort StudiebusinessVenous thromboembolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-lab…

2021

Abstract: Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16 & ndash;26 years of age. We present a phase 3 immunogenicity and safety study of the 9vHPV vaccine in women 27 & ndash;45 versus 16 & ndash;26 years of age. Methods: This international, open-label study (NCT03158220) was conducted in women 16 & ndash;45 years of age. Participants (16 & ndash;26 years, n = 570 and 27 & ndash;45 years, n = 642) received a three-dose 9vHPV vaccination regimen (day 1, month 2, month 6). Month 7 geometric mean titers (GMTs) and seroconversion percentages to anti-HPV 6/11/16/18/31/33/45/52/58 w…

AdultHuman papillomavirusmedicine.medical_specialtyAdolescentAntibodies ViralYoung Adult03 medical and health sciencesNine-valent human papillomavirus vaccineImmunogenicity Vaccine0302 clinical medicine030225 pediatricsInternal medicinemedicineHumansPapillomavirus Vaccines030212 general & internal medicineSeroconversionHPV prophylaxisAdverse effectAgedCervical cancerHuman papillomavirus 16Human papillomavirus 18General VeterinaryGeneral Immunology and Microbiologybusiness.industryPapillomavirus InfectionsAdult vaccinationPublic Health Environmental and Occupational Healthmedicine.diseaseVaccine efficacyConfidence interval3. Good healthVaccinationClinical trialPrecancerRegimenInfectious DiseasesCervical cancerMolecular MedicineFemaleHuman medicinebusinessVaccine
researchProduct

OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.

2015

e16576 Background: Treatment of ovarian cancer (OC) remains very challenging, with 80-85% of the cases still dying after relapse to standard chemotherapy, and novel treatments are urgently needed. Expansion of regulatory T cells (Tregs) is considered the major factor limiting immune responses to OC. Agonist antibodies against the co-stimulatory receptor OX40 have recently demonstrated to abrogate Treg functions and are under clinical evaluation. We thus studied whether OX40 constituted a valid target of OC-associated Tregs. Methods: Treg immunophenotypic analyses were performed by flow cytometry in ascites and OC specimens and studied in association with patients’ outcome Results: CD4+CD25+…

Cancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentFOXP3hemic and immune systemschemical and pharmacologic phenomenaOvarymedicine.diseaseSerous fluidmedicine.anatomical_structureImmune systemOncologyAscitesmedicineCancer researchIL-2 receptormedicine.symptomOvarian cancerbusinessJournal of Clinical Oncology
researchProduct

Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups

2020

Objective Coronavirus disease 2019 (COVID-19) has caused rapid and drastic changes in cancer management. The Italian Society of Gynecology and Obstetrics (SIGO), and the Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) promoted a national survey aiming to evaluate the impact of COVID-19 on clinical activity of gynecologist oncologists and to assess the implementation of containment measures against COVID-19 diffusion. Methods The survey consisted of a self-administered, anonymous, online questionnaire. The survey was sent via email to all the members of the SIGO, and MITO groups on April 7, 2020, and was closed on April 20, 2020. Results Overall, 604 particip…

International CooperationComputer-assisted web interviewingCOVID-19; Health Care Surveys; SARS-CoV-2 Infection; Surgical Oncology; Betacoronavirus; COVID-19; Coronavirus Infections; Female; Genital Neoplasms Female; Gynecologic Surgical Procedures; Gynecology; Humans; Infection Control; International Cooperation; Italy; Medical Oncology; Pandemics; Pneumonia Viral; SARS-CoV-2; Societies Medical; Surveys and Questionnaires; TriageMedical Oncology0302 clinical medicineGynecologic Surgical ProceduresSurgical oncologyGynecologic Surgical ProcedureSurveys and QuestionnairesPandemicHealth careMedicineInfection controlViralStatistics & numerical dataSurveySocieties Medical030219 obstetrics & reproductive medicineObstetrics and GynecologyGeneral MedicineSurgical OncologyOncologyItaly030220 oncology & carcinogenesisSARS-CoV-2 InfectionOriginal ArticleFemaleGenital NeoplasmsCoronavirus Infectionsmedicine.medical_specialtyGenital Neoplasms FemalePneumonia ViralGynecologic oncology03 medical and health sciencesBetacoronavirusMedicalHumansCOVID-19; Health Care Surveys; SARS-CoV-2 Infection; Surgical OncologyPandemicsInfection ControlBetacoronaviruPandemicbusiness.industryCoronavirus InfectionSARS-CoV-2COVID-19PneumoniaTriageSettore MED/40 - GINECOLOGIA E OSTETRICIAHealth Care SurveyGynecologyFamily medicineHealth Care SurveysTriagebusinessSocieties
researchProduct

Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic

2021

Objective Coronavirus disease 2019 (COVID-19) outbreak has correlated with the disruption of screening activities and diagnostic assessments. Endometrial cancer (EC) is one of the most common gynecological malignancies and it is often detected at an early stage, because it frequently produces symptoms. Here, we aim to investigate the impact of COVID-19 outbreak on patterns of presentation and treatment of EC patients. Methods This is a retrospective study involving 54 centers in Italy. We evaluated patterns of presentation and treatment of EC patients before (period 1: March 1, 2019 to February 29, 2020) and during (period 2: April 1, 2020 to March 31, 2021) the COVID-19 outbreak. Results M…

medicine.medical_specialtyendometrial neoplasmsCoronavirus disease 2019 (COVID-19)Endometrial Cancer; COVID-19; Uterine cancer; SARS-CoV-2covid-19; endometrial cancer; sars-cov-2; uterine cancer; female; humans; pandemics; retrospective studies; sars-cov-2; covid-19; endometrial neoplasmspandemicsEndometrial CancerNOCOVID-19; Endometrial Cancer; SARS-CoV-2; Uterine cancerRetrospective StudiePandemicmedicineUterine cancerhumansPatterns of carePandemicObstetricsbusiness.industrySARS-CoV-2Endometrial cancerObstetrics and GynecologyCOVID-19General Medicinemedicine.diseaseEndometrial Neoplasmsretrospective studiesSettore MED/40 - GINECOLOGIA E OSTETRICIAfemaleOncologyOriginal ArticleFemalebusinessHuman
researchProduct

A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma

2006

We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients …

AdultOncologyTRIAL COMPARING CISPLATINmedicine.medical_specialtysecond-line therapy PLATINUM-BASED CHEMOTHERAPYOrganoplatinum CompoundsCyclophosphamidemedicine.medical_treatmentPhases of clinical researchAdenocarcinomaNeutropeniaPACLITAXELchemotherapyGastroenterologySINGLE-AGENTPolyethylene GlycolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineEVALUATETOPOTECANCOMBINATIONCyclophosphamideAgedOvarian NeoplasmsChemotherapybusiness.industrySALVAGE CHEMOTHERAPYoxaliplatinObstetrics and GynecologyCombination chemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisCANCEROxaliplatinRegimenliposomal doxorubicinovarian cancerOncologyDoxorubicinFemaleNeoplasm Recurrence LocalbusinessOvarian cancerFOLLOW-UPmedicine.drug
researchProduct

Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer

2016

Abstract Background - Treatment of ovarian cancer remains very challenging, with 80-85% of the cases still dying after relapse to standard chemotherapy, and alternative treatments are urgently needed. Expansion of regulatory T cells (Tregs) is considered the major factor limiting spontaneous immune responses to ovarian cancer. Agonist antibodies against the co-stimulatory receptor OX40 have recently demonstrated to abrogate Treg functions and are under clinical evaluation. We thus studied whether OX40 constituted a valid target of ovarian cancer-associated Tregs. Methods -Treg immunophenotypic analyses were performed by flow cytometry in ascites and ovarian cancer specimens and studied in a…

Cancer Researchbusiness.industrymedicine.medical_treatmentImmunologyCancerFOXP3chemical and pharmacologic phenomenaOvarymedicine.diseaseSerous fluidImmune systemmedicine.anatomical_structureCancer immunotherapyImmunologyCancer researchmedicineIL-2 receptorbusinessOvarian cancerCancer Immunology Research
researchProduct